SG Americas Securities LLC Sells 1,332 Shares of Xencor, Inc. (NASDAQ:XNCR)

SG Americas Securities LLC reduced its stake in Xencor, Inc. (NASDAQ:XNCR) by 4.2% during the 4th quarter, HoldingsChannel reports. The firm owned 30,555 shares of the biopharmaceutical company’s stock after selling 1,332 shares during the quarter. SG Americas Securities LLC’s holdings in Xencor were worth $702,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. GAMMA Investing LLC grew its stake in shares of Xencor by 31.0% in the 4th quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 508 shares during the period. Point72 Asia Singapore Pte. Ltd. grew its position in Xencor by 8.5% during the 3rd quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 949 shares during the last quarter. KBC Group NV grew its position in Xencor by 63.5% during the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock worth $63,000 after acquiring an additional 1,213 shares during the last quarter. Point72 DIFC Ltd grew its position in Xencor by 10.9% during the 3rd quarter. Point72 DIFC Ltd now owns 13,511 shares of the biopharmaceutical company’s stock worth $272,000 after acquiring an additional 1,333 shares during the last quarter. Finally, Inspire Investing LLC grew its position in Xencor by 10.1% during the 3rd quarter. Inspire Investing LLC now owns 20,530 shares of the biopharmaceutical company’s stock worth $413,000 after acquiring an additional 1,887 shares during the last quarter.

Xencor Stock Down 2.4 %

NASDAQ:XNCR opened at $18.83 on Thursday. The stock’s fifty day moving average price is $23.30 and its two-hundred day moving average price is $21.07. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.23 and a current ratio of 6.23. The company has a market cap of $1.32 billion, a price-to-earnings ratio of -5.88 and a beta of 0.72. Xencor, Inc. has a 52-week low of $15.31 and a 52-week high of $27.24.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($0.71) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.98) by $0.27. The company had revenue of $10.70 million for the quarter, compared to the consensus estimate of $14.59 million. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The firm’s quarterly revenue was down 81.9% on a year-over-year basis. During the same quarter in the prior year, the business posted ($0.40) EPS. On average, analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current year.

Insider Activity

In other news, Director Alan Bruce Montgomery sold 1,421 shares of the stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $27.03, for a total value of $38,409.63. Following the transaction, the director now owns 9,140 shares of the company’s stock, valued at $247,054.20. This represents a 13.46 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP John R. Desjarlais sold 68,684 shares of the company’s stock in a transaction on Monday, November 11th. The shares were sold at an average price of $23.48, for a total transaction of $1,612,700.32. Following the completion of the sale, the vice president now owns 200,104 shares of the company’s stock, valued at approximately $4,698,441.92. This represents a 25.55 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 136,050 shares of company stock valued at $3,277,609 in the last 90 days. 5.23% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on XNCR shares. JPMorgan Chase & Co. increased their price target on Xencor from $27.00 to $28.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Piper Sandler upgraded Xencor from a “neutral” rating to an “overweight” rating and increased their price target for the stock from $20.00 to $30.00 in a research report on Monday, December 2nd. BMO Capital Markets restated an “outperform” rating and set a $34.00 price target (up from $32.00) on shares of Xencor in a research report on Friday, November 8th. Wedbush reaffirmed an “outperform” rating and set a $38.00 price objective on shares of Xencor in a report on Thursday, November 7th. Finally, Wells Fargo & Company assumed coverage on Xencor in a report on Thursday, December 12th. They set an “overweight” rating and a $37.00 price objective on the stock. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, Xencor currently has an average rating of “Buy” and an average target price of $34.88.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.